PBI 05204 - Phoenix Biotechnology

Drug Profile

PBI 05204 - Phoenix Biotechnology

Alternative Names: Oleandrin - Phoenix Biotechnology; PBI-05204

Latest Information Update: 05 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Texas M. D. Anderson Cancer Center
  • Developer Phoenix Biotechnology; United States Army Medical Research Institute of Infectious Diseases
  • Class Antineoplastics; Cardenolides
  • Mechanism of Action Apoptosis stimulants; Fibroblast growth factor inhibitors; NF-kappa B inhibitors; Proto oncogene protein c-akt inhibitors; Transcription factor AP-1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Pancreatic cancer
  • Preclinical Viral infections
  • No development reported Stroke

Most Recent Events

  • 13 Sep 2017 Preclinical trials in Viral infections in USA (unspecified route) before September 2017
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Stroke in USA (PO, Capsule)
  • 01 Apr 2015 Phase-II clinical trials in Pancreatic cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT02329717)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top